BridgeBio Pharma Inc (BBIO) concluded trading on Thursday at a closing price of $32.31, with 2.91 million shares of worth about $94.0 million changed hands on the day. Half year performance of the stock remained positive as price took a surge of 7.74% during that period and on March 13, 2025 the price saw a loss of about -0.86%. Currently the company’s common shares owned by public are about 190.04M shares, out of which, 155.49M shares are available for trading.
Stock saw a price change of 0.25% in past 5 days and over the past one month there was a price change of 3.82%. Year-to-date (YTD), BBIO shares are showing a performance of 17.75% which increased to 11.64% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $21.62 but also hit the highest price of $39.47 during that period. The average intraday trading volume for BridgeBio Pharma Inc shares is 2.92 million. The stock is currently trading -4.84% below its 20-day simple moving average (SMA20), while that difference is down -2.75% for SMA50 and it goes to 15.61% higher than SMA200.
BridgeBio Pharma Inc (NASDAQ: BBIO) currently have 190.04M outstanding shares and institutions hold larger chunk of about 76.14% of that.
The stock has a current market capitalization of $6.14B and its 3Y-monthly beta is at 1.11. It has posted earnings per share of -$2.85 in the same period. It has Quick Ratio of 4.67. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for BBIO, volatility over the week remained 3.60% while standing at 5.72% over the month.
Stock’s fiscal year EPS is expected to drop by -31.31% while it is estimated to increase by 26.78% in next year. EPS is likely to grow at an annualized rate of 41.46% for next 5-years, compared to annual growth of -3.04% made by the stock over the past 5-years.
On September 04, 2024, Piper Sandler Initiated their recommendations, while on March 21, 2024, Raymond James Resumed their ratings for the stock with a price target of $45. Stock get a Market perform rating from BMO Capital Markets on January 31, 2024.
